The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 8 Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 7 6b Any changes to trial outcomes after the trial commenced, with reasons n/a
F o r P e e r R e v i e w
Sample size 7a How sample size was determined 9 7b When applicable, explanation of any interim analyses and stopping guidelines n/a Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence 7 8b
Type of randomisation; details of any restriction (such as blocking and block size) 7
Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
7-8
Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 7-8
Blinding 11a
If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
7-8 11b
If relevant, description of the similarity of interventions n/a Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 9
Results
Participant flow (a diagram is strongly 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48   F  o  r  P  e  e  r  R  e  v  i  e  w   Introduction Long-term follow-up of people with type 1 diabetes (T1D) has demonstrated convincingly that achieving near-normal glucose control through intensive insulin therapy will markedly reduce an individual's risk of both micro-and macrovascular complications [1] . However, despite major improvements in insulin preparations and delivery systems, glycaemic targets are not achieved in the majority of individuals with T1D [1] . A major limitation to achieving glycaemic targets in T1D is the fear of hypoglycaemia. Hypoglycaemia in T1D develops because of profound defects in the normal counterregulatory response, cardinal features of which are; (i) the inability to suppress exogenous insulin, (ii) loss of pancreatic alpha-cell hypoglycaemia-sensing leading to a failure to release the primary counterregulatory hormone, glucagon, and (iii) markedly suppressed catecholaminergic and symptomatic counterregulatory responses to hypoglycaemia (reviewed in [2, 3] ). The first two of these defects is present in all individuals with T1D by 5-years from disease diagnosis, while subnormal symptom and catecholamine responses to hypoglycaemia are present in the majority by 10 years disease duration [4] . Collectively, suppressed catecholaminergic and symptomatic responses to hypoglycaemia, as well as higher thresholds (lower glucose levels) for triggering these responses is referred to as impaired awareness of hypoglycaemia (IAH), which conservatively affects around 25% of people with T1D [5] . IAH is associated with up to a 6-fold increase in the frequency of severe hypoglycaemia in T1D [5] .
Sup fig 1
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The major risk factor leading to the development of IAH is hypoglycaemia itself, with repeated exposure to hypoglycaemia leading to suppression of subsequent counterregulatory responses, while conversely strict hypoglycaemia avoidance restores counterregulatory responses [3] . Clinical interventions aimed at improving hypoglycaemia awareness have therefore largely focused on educational strategies that minimize exposure to hypoglycaemia [2] . Although promising results are being achieved through these approaches, none have to date been able to fully restore hypoglycaemia awareness and as such it seems likely that in addition to educational and behavioural programmes, pharmacological interventions will be required to minimize hypoglycaemia exposure in T1D. Noninsulin adjunct therapies, particularly those targeting pancreatic α-cell glucagon production, have been the subject of recent interest in T1D therapeutics [6, 7] . In T1D there is a failure to release glucagon in response to hypoglycaemia [8] , and a paradoxical increase in both basal and meal-stimulated glucagon release [9] . This in part explains why higher doses of exogenous insulin are required in T1D to achieve glucose levels within the normal physiological range and hyperinsulinaemia contributes directly to the increased hypoglycaemia risk in T1D. Dipeptidyl-peptidase 4 inhibitors (DPP4i), a class of orally active compounds that increase circulating levels of glucagon-like peptide 1 (GLP-1) and gastrointestinal peptide (GIP) [10] , have been shown to suppress basal and post-prandial glucagon [10] [11] [12] [13] , but do not appear to further suppress glucagon secretion during hypoglycaemia [13] .
This raises the intriguing possibility that DPP4i co-therapy in T1D through restoring basal and mealrelated glucagon secretion will reduce insulin requirements, which together reduce glucose variability and subsequently reduce exposure to mild or moderate hypoglycaemia. The indirect effect of this will be to improve CNS (hypothalamic) glucose sensing leading to improved hypoglycaemia counterregulation and awareness. To directly test this hypothesis, we designed a 12-week double blind, randomized, crossover study in individuals with established c-peptide negative T1D. The primary outcome measure was the magnitude of the counterregulatory symptom and hormone responses during a subsequent hyperinsulinaemic hypoglycaemic clamp study, the gold standard for assessing hypoglycaemia responses T1D.
Methods
Study population
This was a single-centre, double blind, placebo-controlled randomized trial. Ethical approval was obtained from an independent research ethics committee and the Medicines Healthcare Products
Regulatory Agency (MHRA)). The study was carried out in accordance with the Declaration of Helsinki, and written informed consent obtained from all participants before inclusion in the study.
Adult subjects (N=14) with C-peptide negative T1D with disease duration >5yrs were recruited and underwent medical screening (Supplementary Figure 1) . Exclusion criteria were; previous history of pancreatic or liver disease, significant microvascular disease, taking drugs that affect CYP3A4 metabolism, pregnancy/breast feeding or a history of seizures. Baseline demographic and information on current diabetes management was collated. All patients had assessment of their hypoglycaemic awareness through utilization of the Gold questionnaire [14] .
Consenting participants had an initial 3-4 week baseline period where they underwent two blinded continuous glucose-monitoring (CGM) periods for at least 5 days (one at the start and one at the end).
The first blinded CGM (iPRO) was used for education purposes -following this each participant had their insulin, dietary and exercise regimes completely reviewed by a single investigator for consistency and carbohydrate ratios reviewed by a single dietician. Treatment of hypoglycaemia was re-iterated with an emphasis on quick recognition and treatment of all hypoglycaemic episodes. These were all done in a one-to-one manner. A second blinded CGM was performed after a minimum of [3] [4] weeks and the data from this was used as a baseline for calculation of glycaemic variability (GV) indices prior to entry into the drug treatment phase. During each CGM, participants were required to fill in the iPRO blood glucose-recording diary for calibration purposes during the 5-7 day monitoring period. This involved self-monitoring of blood glucose (SMBG) at least 3 times a day prior to meals and an additional reading prior to bed. In addition, participants were also encouraged to perform 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w SMBG during all symptomatic hypoglycaemia episodes, and to record all levels below 3.5mmol/L (frequency of hypoglycaemia measures). The data sheet from the iPRO web based software was exported to EasyGV [15] , an excel-enabled workbook. This program uses macros to calculate 10 different measures of glycaemic variability from continuous glucose monitoring data using a simple interface. For the purposes of this study, we focused on Low Blood Glucose Index (LBGI) and Average Daily Risk Range (ADRR). LBGI [16] is a measure of the burden of hypoglycaemia during a period of measurement. Unlike other measures of glycaemic variability, it corrects for the degree of skewness of the glucose range. ADDR [17] has been designed to equally be sensitive to hypoglycaemia and hyperglycaemia, being shown to be the best predictor for extremes of the glucose range. These measures are thought to be the best predictors of glucose variability and have been shown to be strongly associated with severe hypoglycaemia risk [17, 18] . HbA1c, insulin doses and weight were also recorded prior to the first treatment phase.
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Subsequently, subjects were enrolled into 2 groups using a randomized block design. Subjects were randomized in blocks of 4 using a computer generated randomization sequence generator. The research team issued a prescription to clinical trials pharmacy located at Ninewells Hospital. The capsules were then dispensed to the participant for each 3-month treatment period (one bottle of capsules for each month's treatment). Both participant and research team member were blinded to the dispensing.
Seven subjects were in each treatment sequence. Sequence A received placebo for the first 12 weeks, before receiving the DPP4i for the second arm. Sequence B was in reverse order to Sequence A. All subjects were advised to continue their usual diabetes, dietary and exercise regime during the entire trial. Subjects were contacted on a weekly basis for the first month, and then monthly thereafter.
During each contact, adverse events were recorded and advice provided as required on insulin dose adjustment.
Subjects were provided with a single daily oral 5mg dose of the DPPi inhibitor saxagliptin (Onglyza ®, Bristol Myers Squibb) or placebo for 12 weeks. Both placebo and Saxagliptin were encapsulated to ensure they were identical in appearance. At the end of each 12-week period the subjects underwent a further period of blinded CGM (at least 5 days), blood samples were taken and each subject underwent a hyperinsulinaemic hypoglycaemic clamp study to assess the magnitude of their counterregulatory responses. Participants had at least a 2-week washout period before entering the second arm of the trial.
Hyperinsulinaemic hypoglycaemic clamp study
Overnight-fasted subjects reported to the Clinical Research Centre, Dundee at 8.00am. All subjects were asked to avoid hypoglycaemia in the 48 hrs prior to the clamp study and this was subsequently confirmed via CGM. A cannula was inserted into the non-dominant hand, and placed in a heated box 
Blood sampling and analyses
Samples were centrifuged to separate the plasma within 2 hours, and then stored at -80 c prior to assay. Hormones (Insulin-RIA-Diasorin; CV inter -6.7%, intra -5.8%), (Glucagon-RIAMilliporeUK; CV inter 4.9%, intra 8.8%), (Adrenaline-EIA-Alpco; CV inter 22%, intra 16%),
(Noradrenaline-EIA-Alpco; CV inter 16%, intra 22%) were measured by ELISA, and samples were analysed in duplicate according to the manufacturer's instructions.
Symptoms and cognitive function tests
Subjects rated hypoglycaemia symptoms three times over the 40-minute euglycaemic period and every 20mins during the hypoglycaemic plateaus. Symptoms were scored on a validated questionnaire, the Edinburgh Hypoglycaemia Scale, scoring from 1 (not at all) to 7 (very severe) on a visual analogue scale [19] .
Cognitive function was assessed using Trail Making B(TMB) [20] and Digit symbol substitution (DSS) tasks, which are known to be sensitive to hypoglycaemia [21] . To minimize learning effects, all subjects had practiced both tasks. (5-7 days prior to the clamp study and also twice at the start of the clamp study)
Statistical analysis
The hypothesis predicted that DPP4i would reduce exposure to hypoglycaemia leading to improved CNS hypoglycaemia detection and subsequently enhanced adrenaline responses to subsequent hypoglycaemia. This was therefore the pre-specified primary outcome measure. Prior power calculations indicated that 12 subjects were needed for a matched analysis, with 80% power to detect a difference in change of 450pmol/L with SD of 500 and an alpha of 0.05, two sided. This difference in the adrenaline response was chosen based on previous published work [22] . Additional subjects were recruited to account for a potential 25% dropout rate. Secondary outcomes included insulin 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w requirements, HbA1c, glucose variability indices, frequency of hypoglycaemia, hypoglycaemic awareness, and glucagon response during hypoglycaemia. Statistical analyses were conducted using Graphpad Prism 6 and p<0.05 was considered statistically significant. Normally distributed data were compared using paired samples t tests, while non-normally distributed data were compared using the Wilcoxon signed rank test. Repeated measures ANOVA was used to determine differences in other parameters measured over time, with t-testing used to localise effects where indicated. No order effects were noted in any of the subsequent analyses. 
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Results
Recruitment was between
Hyperinsulinaemic hypoglycaemia studies
Glucose profiles during the hyperinsulinaemic clamps studies were well matched with no effect of Placebo vs. Saxagliptin, respectively (see Figure 1F ). 
Glycaemic control and body weight
There was no overall effect of saxagliptin on glycaemic control [HbA1c F(1,11)=2.49 p=0.14], or daily insulin dose [F(1,11)=0.069 p=0.80] ( Table 2 ). During each treatment phase the change in
HbA1c from pre-treatment levels was small (+0.3mmol/L with saxagliptin and -1.6mmol/L with placebo) and did not differ significantly between groups (p=0.61). There was no effect of saxagliptin on weight [mean increase of 0.24kg with saxagliptin and 0.07kg with placebo; F(1,11)=0.40 p=0.54].
Glucose variability
Adverse events
No serious adverse events were reported during the trial. Other adverse events reported were infrequent (<10%), mild and did not differ with placebo or Saxagliptin therapy.
Discussion
Antecedent hypoglycaemia is the major risk factor that leads to the development of IAH, which in turn markedly increases the risk of severe hypoglycaemia [3] . Conversely, hypoglycaemia avoidance strategies improve counterregulatory responses to subsequent hypoglycaemia when tested formally using the clamp technique [23, 24] . Hypoglycaemia in T1D results in a large part from nonphysiological and unregulated hyperinsulinaemia as well as dysregulated glucagon secretion. As a consequence of this specialised glucose sensing neurons in the brain are exposed to repeated hypoglycaemia leading to a series of molecular adaptations that results in reduced catecholaminergic (adrenaline and noradrenaline) and symptom responses to subsequent hypoglycaemia; clinically referred to as IAH [3] . Therefore, by improving physiological glucagon secretion in T1D, it should be possible to both reduce insulin requirements and propensity to mild-moderate hypoglycaemia, which in turn should reduce the central drive to supress catecholaminergic and symptom responses. Recent reports would appear to indicate that DPP4i in T1D can exert this effect on glucagon secretion [10] [11] [12] [13] , and consistent with the underlying hypothesis, Ellis et al. [12] reported that 4-weeks of sitagliptin adjunct therapy in T1D significantly improved glucose variability as assessed by M100, Glycaemic
Risk Assessment Diabetes Equation and J-index. In contrast, the current study found no effect of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w DPP4i in any measure of GV, self-reported hypoglycaemia frequency or insulin-dose, and subsequently no overall effect on hypoglycaemia counterregulation. Although a mixed-meal test was not performed to examine whether 12-weeks DPP4i consistently supressed basal and post-prandial glucagon levels, it seems unlikely based on our data that any significant impact on alpha-cell glucagon secretion would have been detected. Interestingly, in the recent LIBRA trial the GLP-1 receptor agonist liraglutide actually induced a paradoxical rise in post-prandial glucagon in T2D subjects the first evidence of which emerged at around 12 weeks treatment duration [25] . Therefore, and consistent with our findings, any benefit of DPP4i in T1D, at least in terms of alpha-cell suppression, may be short-lived and unlikely to translate into significant improvements in glucose variability.
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In addition, no benefit of DPP4i on glycaemic control was found in the current study. While the study was not powered to detect anything other than large effects, the very small change in HbA1c seen following 12-weeks co-therapy would suggest that any clinical benefit would be minimal. In contrast, Farngren et al. [13] reported that 28 days prior therapy with the DPP4i vildagliptin in T1D had a small benefit in terms of HbA1c reduction, and Ellis et al. [12] reported that 4-weeks of sitagliptin adjunct therapy in T1D significantly improved HbA1c (-2.91± 1.16 mmol/l). However, the latter was a short duration trial with no washout period, and there was a marked Hawthorne effect suggesting that increased contact with health care personal and more frequent monitoring played a large part in the improvements seen. Others have also reported no effect of DPP4i on glycaemic control in T1D [26] .
The main limitations of the study were that the assessment of glucose variability and hypoglycaemia frequency was made during periods of CGM over the 6 days of measurement and longer periods of assessment may have been more representative. However the robust methodology involved in the clamp studies is very suggestive that hypoglycaemia frequency was not reduced. Finally, we were not able to measure GLP-1, glucagon and c-peptide responses to a standard meal in the current trial so cannot say for certain that saxagliptin therapy in T1D was ineffective at improving post-prandial glucose and glucagon responses.
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